Neratinib maleate - Generic Drug Details

What are the generic sources for neratinib maleate and what is the scope of freedom to operate?

Neratinib maleate is the generic ingredient in one branded drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Neratinib maleate has two hundred and sixteen patent family members in thirty-six countries.

One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for neratinib maleate

International Patents:	216
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for neratinib maleate
DailyMed Link:	neratinib maleate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for neratinib maleate

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for neratinib maleate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 2
National Cancer Institute (NCI)	Phase 1
Korea University Guro Hospital	Phase 2

See all neratinib maleate clinical trials

Generic filers with tentative approvals for NERATINIB MALEATE

Applicant	Application No.	Strength	Dosage Form
		40MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for neratinib maleate

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for neratinib maleate

L01EH	Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for NERATINIB MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NERLYNX	Tablets	neratinib maleate	40 mg	208051	1	2021-07-19

US Patents and Regulatory Information for neratinib maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes

Expired US Patents for neratinib maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017

International Patents for neratinib maleate

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4218760
Japan	5681108
Japan	2021185200	（Ｅ）−Ｎ−｛４−［３−クロロ−４−（２−ピリジニルメトキシ）アニリノ］−３−シアノ−７−エトキシ−６−キノリニル｝−４−（ジメチルアミノ）−２−ブテンアミドのマレイン酸塩およびその結晶形態 (MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE, AND CRYSTALLINE FORMS THEREOF)
Japan	2025185115
China	115990181

Supplementary Protection Certificates for neratinib maleate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3000467	C20230025	Finland
4066821	CA 2025 00028	Denmark		PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180831
3000467	122023000045	Germany		PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180831
3000467	C202330029	Spain		PRODUCT NAME: NERATINIB; NATIONAL AUTHORISATION NUMBER: EU/1/18/1311; DATE OF AUTHORISATION: 20180831; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1311; DATE OF FIRST AUTHORISATION IN EEA: 20180831
4066821	C20250029	Finland

Market Dynamics and Financial Trajectory for NERATINIB MALEATE

Last updated: March 4, 2026

What is the current market landscape for NERATINIB MALEATE?

Neratinib maleate is an irreversible pan-HER tyrosine kinase inhibitor, primarily approved for early-stage HER2-positive breast cancer after trastuzumab therapy. It was approved by the FDA in July 2017 under the brand name Nerlynx (Neratinib) and is marketed by Puma Biotechnology.

Global sales of Neratinib reached approximately $150 million in 2022, with North America accounting for about 70%. The drug’s income has grown annually at roughly 20% since 2019, driven by increased adoption in the adjuvant setting and expanding indications. The drug has received regulatory approvals in Japan and the European Union, but sales outside the U.S. remain limited due to reimbursement barriers and competition.

How does the competitive landscape shape the market?

Competitors include:

• Trastuzumab (Herceptin): Standard of care for HER2-positive breast cancer, with global sales exceeding $8 billion annually.

• Pertuzumab (Perjeta): Added in combination with trastuzumab for early and metastatic settings, with sales around $4 billion annually.

• Tucatinib (Tukysa): Approved in 2020 for metastatic HER2-positive breast cancer, generating roughly $200 million in revenue in 2022.

Neratinib’s unique positioning as an extended adjuvant therapy offers a niche, but it faces competition from combination regimens involving monoclonal antibodies. Its market share remains modest, approximately 8-10% within the HER2-positive landscape, owing to limited adoption and side effect profiles such as diarrhea.

What regulatory and clinical developments influence its trajectory?

• FDA approvals: 2017 for early-stage HER2-positive breast cancer post-trastuzumab.

• Ongoing trials: Investigations into its use in metastatic settings and other HER2-overexpressing cancers could expand indications.

• Guideline recommendations: NCCN guidelines include Neratinib as a preferred adjuvant option, bolstering future prescriptions.

• Safety concerns: High incidence of diarrhea, requiring management strategies that may limit prescribing.

What financial factors impact Neratinib's growth prospects and revenue?

• Pricing: Approved in the U.S. at approximately $10,000 per month, depending on the dosage. Reimbursement varies, impacting access.

• Market adoption: Slow in some regions due to safety concerns and payer restrictions. In the U.S., around 50,000 eligible patients annually are estimated, with an adoption rate of 25-30%.

• Patent status: Patent protection expires in 2025 in the United States, opening opportunities for generic competition which could drive prices down and reduce revenue.

• R&D investments: Puma continues clinical trials to expand indications, which could influence future revenue streams.

How do patent and regulatory timelines influence revenue?

Patent expiration in 2025 in the U.S. will enable generic manufacturers to enter the market, likely causing a sharp decline in clinical price point and revenue. Historically, similar drugs experience a 50-70% revenue drop post-generic entry within 2-3 years.

Regulatory hurdles or extension approvals for new indications could mitigate revenue decline by expanding off-label use or new approvals, but no such developments are currently announced.

What are the future projections?

• Short-term (2023-2025): Revenue growth continues as use expands within existing indications. Market share stabilizes with increased awareness and guideline positioning.

• Post-Patent (2025+): Revenue could decline by 60-70% within three years of generic entry unless new indications secure approval or pricing strategies adapt.

• Long-term: Potential for line extension into other HER2-driven cancers exists but remains speculative without specific clinical data.

Summary table of key financial metrics:

Metric	2022 Actual	2023 Estimate	2024 Forecast	2025 and Beyond
Revenue (USD millions)	$150	$180	$180	$60 (post-generic)
Market share	8-10%	Slight increase	Stable	Decline
Patent expiry	2025	—	—	—
CAGR (2019-2022)	20%	15-20%	Stabilization	Decline post-generic entry

Key Takeaways

• Neratinib maleate is a niche treatment within HER2-positive breast cancer, with revenues driven by approvals and clinical adoption.
• Revenue growth is supported by expanded guidelines but constrained by safety concerns and payer reimbursement.
• Patent expiry in 2025 will likely result in significant revenue decline, unless new indications or formulations extend market life.
• Competition from monoclonal antibodies limits market share; NERATINIB’s place hinges on its ability to demonstrate benefit in combination or refractory settings.
• Clinical trials exploring new uses could influence future market dynamics, contingent upon regulatory approval.

FAQs

1. What factors could delay generic competition for Neratinib?
Patent extensions, new formulation patents, or regulatory data exclusivities could postpone generic entry, maintaining higher prices longer than the patent expiration date suggests.

2. How does Neratinib compare to Tucatinib in efficacy?
Direct comparative data is limited. Tucatinib has demonstrated efficacy in metastatic settings with a tolerable safety profile, possibly making it a competitor in certain lines of therapy.

3. What adverse effects limit Neratinib’s use?
Diarrhea is the most common, affecting up to 95% of patients, with severe cases around 20%. Management strategies are necessary to optimize adherence.

4. Are there upcoming trials that might expand Neratinib’s indications?
Yes, ongoing studies are evaluating its use in metastatic HR-positive/HER2-positive breast cancer and other HER2 overexpressing tumors. Results could influence future market expansion.

5. How do reimbursement policies affect Neratinib’s market penetration?
Reimbursement hurdles in several regions, especially outside the U.S., restrict access. Favorable insurance policies and price negotiations could improve adoption.

References

[1] Puma Biotechnology. (2022). Neratinib (Nerlynx) Prescribing Information. Retrieved from https://www.puma-biotechnology.com

[2] IQVIA. (2022). Global Oncology Market Report.
[3] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer.
[4] U.S. Food and Drug Administration. (2017). Neratinib Approval Letter.
[5] EvaluatePharma. (2023). World Preview 2023: Outlook to 2028.